advertisement
Abstract #6507 Published in IGR 3-2
Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension
Michaud JE; Friren BAmerican Journal of Ophthalmology 2001; 132: 235-243
PURPOSE: To compare topical brinzolamide 1% twice daily with dorzolamide 2% twice daily, each given with timolol 0.5% twice daily, for safety, and the effects on intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. METHODS: This double-blind, randomized, active controlled, parallel group study was conducted multinationally at 31 sites, in 241 patients as above, with assessments at baseline and monthly during three months of treatment. The primary end point was a diurnal reduction of trough/peak IOP from a timolol 0.5% twice daily baseline. RESULTS: Both treatment regimens reduced IOP significantly at all time points (p < 0.001): brinzolamide plus timolol by -3.6 to -5.3 mmHg (-14.2 to -21.9%), dorzolamide plus timolol by -6.6 to -5.1 mmHg (-14.1 to 21.2%). Clinically relevant IOP reductions (decreases of 5 mmHg or greater, or absolute IOP values of 21 mmHg or less) were manifested by 50.0-89.3% of patients under brinzolamide plus timolol and by 43.9-85.4% under dorzolamide plus timolol. The treatments were equivalent in mean IOP-lowering. In general, both regimens were well tolerated. However, more patients (p = 0.001) experienced at least one adverse event with dorzolamide plus timolol (32.8%) compared with brinzolamide plus timolol (14.7%); also, more patients (p = 0.001) experienced ocular discomfort (stinging and burning) after dorzolamide plus timolol (13.1%) than after brinzolamide plus timolol (1.7%). CONCLUSIONS: In terms of IOP reduction, brinzolamide 1% twice daily was equivalent to dorzolamide 2% twice daily, each added to timolol 0.5% twice daily, but brinzolamide produced significantly less ocular burning and stinging.
Dr J.E. Michaud, Alcon Laboratories (UK) Ltd., Pentagon Park, Boundary Way, Hemel Hempstead, Herts HP2 7UD, UK. jean-eric.michaud@alconlabs.com
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
